Status:

UNKNOWN

Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema

Lead Sponsor:

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborating Sponsors:

Novartis

Conditions:

Proliferative Diabetic Retinopathy

Diabetic Macular Edema

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

To investigate ranibizumab's benefit on prevention of early postoperative vitreous haemorrhage in PDR-DME patients receiving vitrectomy.

Detailed Description

Primary Objective: To investigate ranibizumab's benefit on prevention of early postoperative vitreous haemorrhage in PDR-DME patients receiving vitrectomy. Secondary Objective:To investigate ranibizu...

Eligibility Criteria

Inclusion

  • Age≥18 years old;
  • Type I or II diabetes mellitus, clinically diagnosed as diabetic macular edema
  • Diagnosed as proliferative diabetic retinopathy and pas plana vitrectomy (PPV) is required to undergo due to non-absorbent vitreous hemorrhage (VH), fibrovascular proliferation with vitreoretinal adhesions or tractional retinal detachment (TRD); or active severe proliferative retinopathy not responding to previous panretinal laser photocoagulation; as well as other indications of PPV at the investigator's discretion
  • Ability to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion

  • Pregnancy or lactation;
  • History of stroke, peripheral vascular disease, angina or myocardial infarction within six months
  • Intraocular treatment with corticosteroids, anti-vascular endothelium growth factor or intraocular surgery within 45 days preceding baseline;
  • Clinically confirmed intraocular pressure (IOP) \>=21 mmHg, uncontrolled glaucoma or iris neovascularization in either eye

Key Trial Info

Start Date :

September 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2022

Estimated Enrollment :

142 Patients enrolled

Trial Details

Trial ID

NCT04464694

Start Date

September 1 2020

End Date

June 1 2022

Last Update

July 9 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Ningbo Eye Hospital

Ningbo, Zhejiang, China, 315012

2

Eye & Ent Hospital of Fudan University

Shanghai, China, 2000831

3

Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

Shanghai, China, 2000892